Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5714493A · kind A · utility
110Cited by
13References
1Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 4, 1996 |
| Grant date | Feb 3, 1998 |
| Priority date | — |
| Expiry date | Jun 4, 2016 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D471/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to the treatment of intimation in a patient suffering from such disorder. More specifically, the invention relates to mono- and/or bicyclic aryl or heteroaryl quinazoline compounds in the treatment of inflammation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.